Last $8.47 USD
Change Today -0.18 / -2.08%
Volume 392.3K
POZN On Other Exchanges
As of 8:10 PM 04/15/14 All times are local (Market data is delayed by at least 15 minutes).

pozen inc (POZN) Snapshot

Previous Close
Day High
Day Low
52 Week High
01/21/14 - $8.99
52 Week Low
05/8/13 - $3.49
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for POZEN INC (POZN)

Related News

No related news articles were found.

pozen inc (POZN) Related Businessweek News

No Related Businessweek News Found

pozen inc (POZN) Details

POZEN Inc., a pharmaceutical company, develops products for the treatment of acute and chronic pain, and pain related conditions in the United States. The company’s products include Treximet for acute treatment of migraine attacks with or without aura in adults; and VIMOVO for the relief of the signs and symptoms of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis, as well as to decrease the risk of developing gastric ulcers in patients at risk of developing non-steroidal anti-inflammatory drugs (NSAID)-associated gastric ulcers. The company also provides PA32540 for secondary prevention of cardiovascular and cerebrovascular disease in patients at risk for gastric ulcers. It has collaborations with GlaxoSmithKline for the development and commercialization of proprietary combinations of a triptan and a long-acting NSAID; and with AstraZeneca AB for the development and commercialization of proprietary fixed dose combinations of the proton pump inhibitor esomeprazole magnesium with the NSAID naproxen. The company was founded in 1996 and is headquartered in Chapel Hill, North Carolina.

16 Employees
Last Reported Date: 03/6/14
Founded in 1996

pozen inc (POZN) Top Compensated Officers

Co-Founder, Chairman, Chief Executive Officer...
Total Annual Compensation: $574.5K
Chief Financial Officer and Senior Vice Presi...
Total Annual Compensation: $342.8K
Chief Medical Officer
Total Annual Compensation: $361.2K
Senior Vice President, General Counsel and Se...
Total Annual Compensation: $320.3K
Compensation as of Fiscal Year 2012.

pozen inc (POZN) Key Developments

POZEN Inc. Submits Final Study Report for PA8140/PA32540 Phase 1 Study on Schedule

POZEN Inc. announced that they have submitted the final study report for the Phase 1 study comparing the pharmacokinetic profile of the omeprazole component of PA8140 tablets to that of PA32540 tablets as agreed with the U.S. Food and Drug Administration.

POZEN Inc. Announces Unaudited Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2013

POZEN Inc. announced unaudited earnings results for the fourth quarter and full year ended December 31, 2013. For the fourth quarter of 2013, the company reported total revenue of $4.7 million compared to $1.4 million a year ago. Net loss was $2.2 million or $0.07 loss per diluted share compared to net loss of $6.1 million, or $0.20 per share on a diluted for the fourth quarter of 2012. For the year, the company revenue of $10.3 million compared to $5.3 million in 2012, up 93% year over year. Net loss was $16.7 million or $0.55 per diluted share compared to net loss of $25.3 million or $0.84 per diluted share for the same period in 2012.

POZEN Inc., Q4 2013 Earnings Call, Mar 05, 2014

POZEN Inc., Q4 2013 Earnings Call, Mar 05, 2014


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
POZN:US $8.47 USD -0.18

POZN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
AstraZeneca PLC 3,746 GBp +23.00
BioDelivery Sciences International Inc $7.13 USD -0.05
Endo International PLC $56.28 USD -0.50
Hi-Tech Pharmacal Co Inc $43.50 USD +0.16
Sunesis Pharmaceuticals Inc $5.10 USD -0.20
View Industry Companies

Industry Analysis


Industry Average

Valuation POZN Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 25.6x
Price/Book 14.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales 22.6x

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact POZEN INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at